As mentioned above, targeting the EGF system has already become an established treatment modality in some types of tumours (Sridhar et al, 2003; Ranson, 2004), and has been shown to inhibit growth of NE GI tumour cells (Höpfner et al, 2003). This evidence concerns the gene EGF and digestive system neoplasm.